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Introduction
Ischemic optic neuropathies are the most frequent
acute optic neuropathies in patients >50 years of age.1,2
Depending on the segment of optic nerve affected,
they are subdivided into anterior and posterior ischemic
optic neuropathies. Optic disc edema from ischemia
to the anterior nerve is, by definition, present in ante-
rior ischemic optic neuropathy (AION) and absent in
posterior ischemic optic neuropathy (PION). AION is
much more common than PION, accounting for 90%
of cases of optic nerve ischemia.
AIONs are subdivided into nonarteritic and arteritic
etiologies. Arteritic anterior ischemic optic neuropathy
(AAION), classically due to inflammation of mid-sized
arteries, is an ophthalmologic emergency, requiring
prompt recognition and treatment to prevent devastat-
ing blindness. About 90–95% cases of AION are non-
arteritic anterior ischemic optic neuropathy (NAAION).
Various therapies for ischemic optic neuropathy have
been studied, including medical and surgical treatments,
though without definitive beneficial results. Here, we
addressed only patients with NAAION and PION at
Kaohsiung Veterans General Hospital in the past 10
years and excluded AAION patients. Four different
medical therapies were given. We performed retro-
spective chart review to survey the multiple relevant
factors and visual outcomes in these patients.
Methods
In all, 107 Chinese patients were screened; 4 patients
were excluded due to loss to follow-up in later visits.
Chart review was from 1995–2005, and 103 consec-
utive patients (57 males, 55.34%; 46 females, 44.66%)
were included in the study. Their ages ranged from
15 to 91 years old.
The inclusion criteria were sudden onset of loss of
vision, relative afferent papillary defect (bilateral disease
excepted), optic disc edema (in NAAION), and nerve
fiber layer defect on visual field testing. Ocular medical
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history was obtained and complete eye examination
was performed.
Patients were excluded if they had clinical features
that suggested disorders other than nonarteritic ischemic
optic neuropathy (NAION), such as a significantly ele-
vated sedimentation rate or elevated C-reactive protein
level. A history of inflammatory or infectious diseases
was also eliminated by detailed history-taking or relative
systemic and laboratory examination. If other central
nervous system lesions were suspected, imaging study
was arranged.
Subjects were divided into 4 groups depending 
on their treatment modes. Group 1 consisted of 78
patients who received supportive oral medication, e.g.
aspirin, vasodilator and vitamin B complex. Group 2
consisted of 8 patients who had oral prednisolone.
Group 3 consisted of 10 patients who underwent pulse
methylprednisolone therapy. Group 4 consisted of 7
patients who were placed under observation only and
did not receive any kind of treatment (Table 1).
Patients’ best corrected visual acuity was measured
by Snellen chart and notated by logMAR. Counting
fingers, hand motion, light perception and no light
perception were assigned the worse possible value in
the logMAR. Visual acuity change for 0.2 logMAR was
regarded as meaningful improvement or worsening.
Vision stabilization was defined as the patient’s vision
not fluctuating in clinic visits for at least 3 times con-
secutively. Within treatment groups, visual outcome was
assessed by t tests. All p values were 2-sided; p < 0.05
was considered statistically significant.
Results
The study population comprised 14 patients with
PION and 89 patients with NAAION. Fifty-seven pa-
tients were male. The male to female ratio was 1.24:1.
Patients’ systemic conditions were carefully reviewed.
Hypertension had a prevalence of 58.3%, followed by
diabetes mellitus (36.9%). Mean age at disease attack
was 61±12 years (range, 15–91 years) (Figure 1). Most
patients were > 50 years old (84.5%).
Visual acuity improving by 0.2 logMAR was re-
garded as meaningful improvement. The final vision
outcome showed that 36 of 103 patients (34.95%) had
vision improvement, 54 patients (52.43%) had little
or no change, and 13 patients (12.62%) had a worsen-
ing of vision. The visual acuity changes in each group
are listed in Table 1. Because of the insufficient case
number in some groups, no significant visual improve-
ment difference between treatment groups was found
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Figure 1. Distribution of age at disease attack.
Table 1. Vision change in each treatment group
Group
Oral medication Oral prednisolone Methylprednisolone pulse Observation
(n = 78) (n = 8) therapy (n = 10) (n = 7)
Vision change (lines), n (%)
Worse > 0.2 logMAR 10 (12.8) 2 (25) 1 (10) 0 (0)
Little or no change 42 (53.8) 2 (25) 6 (60) 4 (57.1)
Improvement > 0.2 logMAR 26 (33.3) 4 (50) 3 (30) 3 (42.9)
(p = 0.24). Age and initial visual acuity also had no
significant influence on vision recovery (p = 0.32 and
p=0.08, respectively) (Table 2). Finally, the mean dura-
tion from symptom onset to vision stabilization was
55 ± 98 days (range, 0 days to > 1 year).
Discussion
The diagnosis of ischemic optic neuropathy requires
complete history-taking and exclusion of other pos-
sible diseases, such as multiple sclerosis, compressive
optic neuropathy or other central nervous system-
related lesions and inflammatory diseases. In younger
patients, Leber’s hereditary optic neuropathy should
also be ruled out.3
The clinician’s primary role in managing patients
with this disorder is exclusion of arteritic causes and
modification of vascular risk factors that might affect
final visual outcome. So, subsequent occurrence in the
second eye might be prevented. The rate of second
eye involvement is 15% in the following 5 years.4
Proper recognition can prevent unnecessary and expen-
sive diagnostic evaluations and unnecessary exposure
of the patient to inappropriate therapies.
There is no established treatment for ischemic
optic neuropathy. Various medical therapies have been
studied, without definitive beneficial results. These
include phenylhydantoin, intraocular vasodilators,
levodopa, intravenous norepinephrine, anticoagulation,
aspirin, and corticosteroids.5–10 It has been theorized
that agents such as brimonidine tartrate or meman-
tine may have a neuroprotective role in ischemic optic
neuropathy; however, human trials have not been
successfully performed.11
In 1989, it was first suggested that optic nerve sheath
decompression surgery (ONDS) may be beneficial in
patients with the progressive form of NAION,12 and
subsequent reports supported these findings.13–15 How-
ever, the results of the Ischemic Optic Nerve Decom-
pression Trial (IONDT) suggested that ONDS for
NAION was not effective and may actually be harmful.6
In this study, the 4 groups had similar visual acuity
outcomes independent of the different treatments,
although the case number was limited. Also, regarding
choice of treatment, we gave more aggressive therapy
in clinically more serious patients (poorer visual acuity
in the very first presentation) and younger patients. But
we did not find any correlation between initial vision
and the treatment patients received with final visual
acuity (p = 0.08).
However, we found that poorer vision at first pres-
entation had greater potential for improvement. On
the contrary, fair vision at the first visit sometimes
worsened in later follow-up. The condition may be due
to early awareness of the disease and no matter what
step we took, the disease continued on its own course.
Age did not play a significant role in prognosis in our
study (p = 0.32).
IONDT reported that 38 of 89 patients (42.7%)
in the follow-up group improved ≥ 3 lines of visual
acuity at 6 months, 40 patients (44.9%) had little or
no change, and 11 patients (12.4%) had a worsening
of vision by ≥ 3 lines.6 However, this rate of improve-
ment is higher than has been previously reported in the
literature.16,17 At the 24-month follow-up, 27 of 87
patients (31.0%) in the follow-up group improved ≥ 3
lines of visual acuity, 41 patients (47.1%) had little
change, and 19 patients (21.8%) had a worsening of
vision by ≥ 3 lines.18 Our result was comparable to
those of previous reports16,17 and the IONDT outcome
at the 24-month follow-up.
The mean time for vision stabilization was 55 days.
But that result is biased because some patients did not
seek medical help at the very beginning. The reason
might be that they did not pay attention to their vision
loss while they still had 1 sound eye. Therefore, this bias
would affect the accuracy of the duration for vision
stabilization.
Interestingly, male gender was slightly predomi-
nant in this NAION series, and this situation is similar
to the prevalence rates of hypertension and hypergly-
cemia in Taiwan. We also found that males had poorer
vision prognosis than females, although this was not
statistically significantly (p = 0.07).
As we know, the risk factors for NAION include
crowding disc, hypertension, diabetes mellitus, smok-
ing, vasculitis, hyperlipidemia, renal failure, and mi-
graine. In this study, we found that the most significant
risk factor for ischemic optic neuropathy was hyper-
tension, in 58.3% of patients (odds ratio, OR = 2.70,
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Table 2. Vision improvement by patient age and initial vision
Cases Vision improvement
(n) (logMAR)*
Age (yr)
< 30 2 0
≥ 30 to ≤ 50 14 −0.23
> 50 87 −0.19
Initial vision (logMAR)
> 1 49 −0.49
1–0.2 40 −0.03
< 0.2 14 0.11
*Vision improvement = stabilized final vision minus initial vision, notated in
logMAR (a negative value represents improvement).
compared with the prevalence rate in Taiwan), followed
by diabetes mellitus in 36.9% of patients (OR = 4.92,
compared with the prevalence rate in Taiwan).19
In conclusion; about 1-third (34.95%) of patients
with NAION had vision improvement regardless of
what treatment they received. And, about half (52.43%)
of all patients showed no change in vision after disease
onset. The average time for vision stabilization was < 2
months. Theoretically, steroids can reduce further tissue
damage caused by edematous nerve head. Presenting
visual acuity, patient age, and treatment received had no
significant influence on the final visual outcome. Finally,
we note that hypertension and diabetes mellitus are the
leading underlying causes of NAION. Potential limi-
tations of our study include its retrospective nature and
selection bias. Because of the low incidence of NAION,
an adequately controlled prospective study would be
difficult but worthy of further workup.
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